DONATE

Free Support Line: 833-275-4222

Walk to End Bladder Cancer

Back to Clinical Trials

Brief Title: Familial and Atypical Urothelial Cancer Registry

Back to Clinical Trials

A Genotype-Phenotype Urothelial Cancer Registry

INTRODUCTION

  • Org Study ID: 09-025
  • Secondary ID: N/A
  • NCT ID: NCT00902590
  • Sponsor: Memorial Sloan Kettering Cancer Center

BRIEF SUMMARY

This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer.

The investigators will look at risk factors to learn more about how these impact cancer. The investigators will also look at genetic markers. These are genes that are found in a known place. They are often associated with a particular trait. If the gene changes in some way, it may predict cancer or response to treatment. The investigators will look for markers in your saliva.

This registry will help us develop better methods of:

Preventing these cancers. Diagnosing these cancers. Treating these cancers.

  • Overall Status
    Active, not recruiting
  • Start Date
    May, 2009
  • Phase
  • Study Type
    Observational

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans

Primary Outcome 1 - Timeframe: 2 years

Primary Outcome 2 - Measure: such as 8q24 & chromosome 3

Primary Outcome 2 - Timeframe: N/A

Primary Outcome 3 - Measure: & candidate genes

Primary Outcome 3 - Timeframe: N/A

Primary Outcome 4 - Measure: include NAT2 & GSTM1

Primary Outcome 4 - Timeframe: N/A

Primary Outcome 5 - Measure: prev found to be assoc with bladder ca risk

Primary Outcome 5 - Timeframe: N/A

Primary Outcome 6 - Measure: are assoc with UC in this study population

Primary Outcome 6 - Timeframe: N/A

CONDITION

  • Urothelial Cancer
  • Renal Pelvis Cancer
  • Ureter Cancer
  • Bladder Cancer

ELIGIBILITY

Inclusion Criteria:
Urothelial Cancer Cases
* Must be ≥ 18 years of age AND

- * Must have a diagnosis of urothelial cancer AND

- * Must be an English-speaker
Non-Cancer Control Group
* Must be ≥ 18 years of age AND

- * Must not have cancer or a personal history of cancer, with the exception of skin cancer. AND

- * Must not be a blood relative of cases AND

- * Must not be a blood relative of another control AND

- * Must be an English-speaker
Family Member Control Group:
In select kindreds with a high prevalence of bladder cancer and/or very early onset bladder cancer, first- and second-degree family members of probands may be contacted by the MSKCC study team and invited to complete the questionnaire and submit a saliva sample.
* Must be ≥ 18 years of age AND

- * Must be a blood relative of a case participant AND

- * Must be an English-speaker
Exclusion Criteria:
* Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Dean Bajorin, MD

Role: Principal Investigator

Affiliation: Memorial Sloan Kettering Cancer Center

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact

Related Stories